Oral Solid Dose Predictions for 2025

New year, new advancements for the industry’s oldest and most beloved dosage form? It’s likely, according to experts. Not surprisingly, industry leaders predict a continued focus on improved adherence via user-friendly dosage forms and designs in both the pharma and nutraceutical spaces.


Users want delivery formats that not only work with their lifestyles but are enjoyable. Technology will also be key to OSD’s future, with advancements in automation, continuous manufacturing and 3D printing helping manufacturers respond to shifting patient demographics and needs. Better equipment efficiency and accuracy will enable manufacturers to stay on top of necessary cost-saving initiatives.

Quality will remain ever-important, as manufacturers continue to wrestle with nitrosamine impurities. On the nutraceuticals side, manufacturers will square off against pharma-level accountability and requirements. And 2025 may be the year that OSD gets in on the weight-loss market frenzy, as new innovations enable manufacturers to overcome bioavailability challenges of oral biologics.

Industry trends will lead to collaborative efforts 

Several trends are likely to arise or accelerate in 2025 across the OSD segment. The push for speed to market in drug approvals will continue, supported by expedited R&D timelines and fast-tracked approvals for OSD products meeting unmet or underserviced therapeutic needs. Technology also will continue its march in the areas of smart manufacturing and packaging. Advancements in these segments will further enable automation, continuous manufacturing and the use of AI, driving the overall digital transformation movement. 

From PCI’s position as a CDMO, we’re seeing much of these trends point toward expanded partnerships and collaborative efforts. Several factors, including the complexity and cost of specialized equipment and the integration of digital technology, inherently lend themselves to forming such strategic partnerships — and the data supports this. The OSD contract manufacturing market was valued at $35.6 billion in 2023 and is anticipated to grow at a CAGR of 5.6% now through 2032. Much of this uptick will be steered by particularly complex OSD formulations, including specialist high-potency drugs and novel drug delivery systems, with oncology claiming a large slice of this pie. 

Dr Rebecca Coutts, Senior Director of Pharmaceutical Development, PCI Pharma Services as featured in 2025 Predictions: Industry Leaders Weigh in on the Future of Oral Solid Dose | Tablets and Capsules Magazine.


We are committed to supporting clients at every stage of the manufacturing cycle, delivering best-in-class services efficiently and effectively.

Find out more about our Solid Oral Dose Solutions.


Our dedicated team of specialists will be happy to discuss any of your Solid Oral Dose questions. Contact us on +1 215-613-3600 (US) or +44 1495 711 222 (UK/EU) or email talkfuture@pci.com

Awards

We take pride in celebrating the accomplishments and accolades that distinguish PCI Pharma Services, our employees, and our services. These achievements are a testament to our commitment to excellence, innovation, and the unwavering dedication of our teams